Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CEACAM5 antibody-drug conjugate BG-C477

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; carcinoembryonic antigen; CEA; CD66e) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-CEACAM5 ADC BG-C477, the monoclonal antibody moiety targets and binds to CEACAM5 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the CEACAM5-expressing cancer cells through an as of yet unknown mechanism of action. This inhibits the proliferation of CEACAM5-expressing tumor cells. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its expression is limited in normal. healthy, adult tissues, but is overexpressed in various cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CEA ADC BG-C477
anti-CEA antibody-drug conjugate BG-C477
anti-CEACAM5 ADC BG-C477
Code name:BG C477
BG-C477
BGC477
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search